Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to keep advanced lung cancer at bay

NCT ID NCT03775486

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a pill called olaparib to an existing immunotherapy drug (durvalumab) works better than the immunotherapy alone to keep advanced lung cancer from getting worse. It involves patients whose cancer has not progressed after initial chemotherapy. The goal is to see if the combination helps control the cancer for longer and is safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Bonita Springs, Florida, 34135, United States

  • Research Site

    St. Petersburg, Florida, 33705, United States

  • Research Site

    Tallahassee, Florida, 32308-5304, United States

  • Research Site

    West Palm Beach, Florida, 33401, United States

  • Research Site

    Kansas City, Missouri, 64132, United States

  • Research Site

    Bethlehem, Pennsylvania, 18015, United States

  • Research Site

    Chattanooga, Tennessee, 37404, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Houston, Texas, 77090, United States

  • Research Site

    Aalst, 9300, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Roeselare, 8800, Belgium

  • Research Site

    Budapest, 1088, Hungary

  • Research Site

    Budapest, 1122, Hungary

  • Research Site

    Debrecen, 4032, Hungary

  • Research Site

    Deszk, 6772, Hungary

  • Research Site

    Farkasgyepü, 8582, Hungary

  • Research Site

    Törökbálint, 2045, Hungary

  • Research Site

    Ahmedabad, 380009, India

  • Research Site

    Ahmedabad, 380053, India

  • Research Site

    Jamnagar, 361008, India

  • Research Site

    Kochi, 682026, India

  • Research Site

    Mysuru, 570021, India

  • Research Site

    Nashik, 422004, India

  • Research Site

    Nashik, 422005, India

  • Research Site

    Nashik, 422009, India

  • Research Site

    Pune, 411001, India

  • Research Site

    Thiruvananthapuram, 695011, India

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Kanazawa, 920-8641, Japan

  • Research Site

    Kurume-shi,, 830-0011, Japan

  • Research Site

    Matsuyama, 791-0280, Japan

  • Research Site

    Nagoya, 460-0001, Japan

  • Research Site

    Sendai, 980-0873, Japan

  • Research Site

    Sunto-gun, 411-8777, Japan

  • Research Site

    Ube-shi, 755-0241, Japan

  • Research Site

    Chihuahua City, 31200, Mexico

  • Research Site

    Culiacán, 80230, Mexico

  • Research Site

    San Luis Potosí City, 78250, Mexico

  • Research Site

    Blaricum, 1261, Netherlands

  • Research Site

    Harderwijk, 3844, Netherlands

  • Research Site

    Tilburg, 5022 GC, Netherlands

  • Research Site

    Bialystok, 15-540, Poland

  • Research Site

    Lodz, 90-302, Poland

  • Research Site

    Poznan, 60-693, Poland

  • Research Site

    Prabuty, 82-550, Poland

  • Research Site

    Arkhangelsk, 163045, Russia

  • Research Site

    Chelyabinsk, 454092, Russia

  • Research Site

    Kursk, 305524, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Nal'chik, 360000, Russia

  • Research Site

    P. Herzen Moscow Oncology Rese, 125284, Russia

  • Research Site

    Saint Petersburg, 197022, Russia

  • Research Site

    Sochi, 354000, Russia

  • Research Site

    Yaroslavl, 150054, Russia

  • Research Site

    Dongjakgu, 07061, South Korea

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Seodaemun-gu, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Suweonsi Paldalgu, 16247, South Korea

  • Research Site

    Dnipro, 49102, Ukraine

  • Research Site

    Kharkiv Region, 61024, Ukraine

  • Research Site

    Kirovohrad, 25006, Ukraine

  • Research Site

    Odesa, 65055, Ukraine

  • Research Site

    Uzhhorod, 88000, Ukraine

  • Research Site

    Zaporizhzhia, 69059, Ukraine

  • Research Site

    Dundee, DD1 9SY, United Kingdom

  • Research Site

    Hull, HU6 7RX, United Kingdom

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER (NSCLC)